Boston Partners’s Legend Biotech LEGN Stock Holding History

Boston Partners’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,196	Closed	-$24K	–	807
2023 Q4	$24K	Buy	+10,196	New	+$646K	﹤0.01%	704

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Boston Partners's LEGN Position: Q1 2024 in Review

Boston Partners sold out of Legend Biotech (LEGN) in Q1 2024, closing a stake of 10,196 shares — an estimated $24K sold.

Boston Partners first reported a position in LEGN in Q4 2023 and held it in 1 quarter. The position peaked at $24K in Q4 2023. 192 funds tracked by Wall St. Rank hold LEGN as of Q1 2024.

Boston Partners reported no remaining Legend Biotech position as of Q1 2024 after selling out during the quarter.
Boston Partners sold 10,196 Legend Biotech shares in Q1 2024, an estimated $24K.
Boston Partners first reported a position in Legend Biotech in Q4 2023 and held it in 1 quarter.
Boston Partners's Legend Biotech position peaked at $24K in Q4 2023.
192 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2024.

Based on Boston Partners's 13F filing for Q1 2024, filed 13 May 2024.